INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice - Top-Institutions - MDSpire

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • By

  • Sameer Sharma

  • Lixian Chen

  • Tianhao Zhou

  • Meenakshi Chawla

  • Anita Ganjoo

  • Shunichiro Okada

  • Salvatore Alesci

  • Krishnan Nandabalan

  • Heather Francis

  • June 9, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Hepatology

  • #2

    Guangxi Medical University
    Guangxi Medical University

    Nanning, Guangxi

    Key Differentiators

    • Hepatology

  • #3

    Jackson Laboratory
    Jackson Laboratory

    Bar Harbor, ME

    Key Differentiators

    • Hepatology

  • #4

    GemPharmatech
    GemPharmatech

    Nanjing, Jiangsu

    Key Differentiators

    • Hepatology

  • #5

    Asahikawa Medical University
    Asahikawa Medical University

    Asahikawa, Hokkaido

    Key Differentiators

    • Hepatology

Original Source(s)

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • by Sameer Sharma, Lixian Chen, Tianhao Zhou, Meenakshi Chawla, Anita Ganjoo, Shunichiro Okada, Salvatore Alesci, Krishnan Nandabalan, Heather Francis

  • June 9, 2026

Related Content

Schisandra chinensis Fructus and its active metabolites for the treatment of metabolic dysfunction-associated steatotic liver disease

TyG-WHtR predicts incident type 2 diabetes mellitus in NAFLD: a 12-year prospective cohort study

Gut decisions based on the liver: prediction of colorectal neoplasia using AI-based liver analysis of routine CT scans